Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM).
M. Wang
Research Funding - Celgene; Millennium; Novartis; Onyx
W. Bensinger
Consultant or Advisory Role - Onyx
Honoraria - Celgene
Research Funding - Onyx
T. Martin
Consultant or Advisory Role - Onyx
Honoraria - Celgene
M. Alsina
Consultant or Advisory Role - Millennium; Novartis
Honoraria - Celgene; Millennium
D. S. D. Siegel
Honoraria - Celgene; Millennium
N. Y. Gabrail
No relevant relationships to disclose
P. Hari
No relevant relationships to disclose
S. Singhal
Consultant or Advisory Role - Celgene; Takeda
Research Funding - Onyx
R. A. Vescio
No relevant relationships to disclose
S. E. Assouline
No relevant relationships to disclose
L. A. Kunkel
Stock Ownership - Onyx; Onyx
M. Vallone
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
A. Wong
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
R. Niesvizky
No relevant relationships to disclose